(Q58354213)

2 July 2019

title

114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide. (English)

1 reference

2 July 2019

author

Vladimir Tolmachev

1

1 reference

2 July 2019

Eva Forssell-Aronsson

3

1 reference

2 July 2019

author name string

Bernhardt P

2

1 reference

2 July 2019

Lundqvist H

4

1 reference

2 July 2019

publication date

1 February 2000

1 reference

2 July 2019

Nuclear Medicine and Biology

published in

1 reference

2 July 2019

volume

27

1 reference

2 July 2019

issue

2

1 reference

2 July 2019

page(s)

183-188

1 reference

2 July 2019

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

[Somatostatin receptor scintigraphy. Methodology, indications, results]

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

The advantages and limits of indium-111 labeling of antibodies. Experimental studies and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Pharmacokinetics of an indium-labeled IgG monoclonal antibody over a prolonged period

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer--dosimetric and biokinetic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Monoclonal antibody targeting of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Somatostatin receptor: scintigraphy and radionuclide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

110Sn/110In—A new generator system for positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

Radionuclides and carrier molecules for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2899%2900096-7

7 January 2021

10.1016/S0969-8051(99)00096-7

Identifiers

DOI

1 reference

2 July 2019

1 reference

2 July 2019